C4 Therapeutics Q1 2026 Earnings Strong EPS Beat Highlights Cost Discipline Amid PreRevenue Stage CTOR Q1 2026 Earnings Deep Losses and Negative Surprise as Company Remains PreRevenue DAKT Q1 2026 Earnings EPS Misses Estimates Stock Rises Despite Disappointing Start WABC Q1 2026 Earnings EPS Beats Estimates as Interest Income Stability Offsets Margin Pressures CICC Q1 2026 Earnings EPS Falls Short of Estimates Stock Slides 06 ANIX Q1 2026 Earnings Narrowed Loss Beats Expectations as Pipeline Advances